Dissemination (Meeting Coverage)

A multidisciplinary, personalized weight loss plan including semaglutide, dietary counseling, and physical therapy helped a patient with severe obesity.

Researchers at the AACE Annual Meeting 2025 found that educating patients to use a diet self-monitoring mobile app improved adherence to a weight loss program.

Patients with inflammatory disorders and acute heart failure experienced more cardiovascular complications despite similar in-hospital mortality.

The annual Peripheral Nerve Society meeting will include a series of mini-symposia on Charcot-Marie-Tooth Disease, peripheral nerve repair, and more.

Forthcoming highlights of the annual meeting of the Peripheral Nerve Society include eight special lectures, including the closing keynote.

A new consensus redefines obesity as a chronic illness and urges better diagnostics, equitable care, and stigma-free, evidence-based interventions.

New research presented at ACC.25 suggests that intensive blood pressure control reduces cardiovascular events and mortality in patients with hypertension.

Research presented at the 2025 AAD Annual Meeting showed that moderate to severe scalp psoriasis was associated with a substantial impact on quality of life.

Study demonstrates that stable BTT patients with second-generation VADs (I5.5) can be safely transitioned from ICU to step-down units, alleviating ICU congestion and providing significant financial benefits.

Researchers called for dermatologists to recognize psoriasis-associated comorbidities, which can be managed more effectively with a multidisciplinary care team.

Collaborating with patients is essential for addressing sleep disturbances and mental health comorbidities, which are under-recognized in psoriasis.

ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.

Patients with melanoma and cIRAEs on immune checkpoint inhibitors face higher toxicity risks but improved survival, warranting close monitoring.

Bempikibart demonstrated durable, clinically meaningful responses in patients with severe alopecia areata in the phase 2 SIGNAL-AA trial.

A recently developed treatment satisfaction tool called the DermSat-7 was valid and reliable for use in psoriasis management and clinical trials.

Research presented at ACC.25 focused on coordination teams and new hospital workflows designed to improve referrals and care quality for cardiology patients.

A digital monitoring program reduced readmission rates and bolstered cardiac rehabilitation enrollment among patients with coronary heart disease.